FDA Approves Two New Medications for Diabetes

Share this content:
FDA Approves Two New Medications for Diabetes
FDA Approves Two New Medications for Diabetes

MONDAY, Sept. 28, 2015 (HealthDay News) -- Two new diabetes treatments, Tresiba (insulin degludec injection) and Ryzodeg (insulin degludec/insulin aspart injection), have been approved by the U.S. Food and Drug Administration.

Tresiba is a long-acting insulin product, the agency said in a news release. It is injected once daily and helps control blood glucose levels in patients with both type 1 and type 2 diabetes. The FDA also approved a related treatment, Ryzodeg, which combines Tresiba and another insulin.

The FDA said in its news release Friday that Tresiba's overall efficacy and safety were evaluated in numerous trials involving more than 3,700 patients with type 1 and type 2 diabetes. The results showed that reductions in HbA1c were comparable to other long-acting insulin products, the agency added.

Tresiba and Ryzodeg should not be used by diabetes patients who have high levels of ketones in their blood, and some common effects include episodes of hypoglycemia, allergic reactions, rash, itching, edema, and weight gain, the agency noted.

Both treatments are made by Novo Nordisk, based in Plainsboro, N.J.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

Rising Fatal Drug Overdoses Linked to Years of Life Lost

Rising Fatal Drug Overdoses Linked to Years of ...

Growth in fatal overdoses linked to increased mortality, years of life lost for non-Hispanic whites

Atherosclerotic CVD Mortality Higher in South Asians in the U.S.

Atherosclerotic CVD Mortality Higher in South Asians in ...

Most of the increased risk can be attributed to increased prevalence of known risk factors

Global Variation in Personal Health Care Access and Quality

Global Variation in Personal Health Care Access and ...

Highest performance in Iceland, lowest in Central African Republic, with variation in rate of progress